
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion is a MedTech company operating in a competitive market with potential risks from bigger players such as Terumo and Medtronic. The company's reliance on its preservation services segment and its dependency on BioGlue revenue pose regulatory and competition risks. Additionally, the company's international operations and foreign revenue are subject to exchange rate risk and regulatory changes. Despite these risks, the company's strong fundamentals and ongoing product development and expansion efforts position it for continued growth and profitability.
Bears say
Artivion is currently experiencing some challenges with its revenue growth, with a slow start in the first quarter of 2026 and a lowered FY26 revenue and adjusted EBITDA guidance. However, there are still positive developments such as the acquisition of Endospan's NEXUS product and the growth potential of the On-X heart valve portfolio. In the long-term, the company's pipeline remains robust with ongoing clinical trials for exciting new products. The company also has a strong balance sheet with a significant amount of cash. Despite the short-term setbacks, Artivion has the potential to continue being a leading producer and distributor of cardiovascular medical devices and technology, making it an attractive investment opportunity in the long run.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares